Wolfgang Abenhardt

1.4k total citations
26 papers, 396 citations indexed

About

Wolfgang Abenhardt is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Wolfgang Abenhardt has authored 26 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 13 papers in Oncology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Wolfgang Abenhardt's work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Cancer Treatment and Pharmacology (7 papers). Wolfgang Abenhardt is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Cancer Treatment and Pharmacology (7 papers). Wolfgang Abenhardt collaborates with scholars based in Germany, Estonia and United States. Wolfgang Abenhardt's co-authors include Raymonde Busch, Michael Kneba, Barbara Eichhorst, Clemens‐Martin Wendtner, Matthias Ritgen, Michael Hallek, Volker Heinemann, Carmen D. Schweighofer, Ludwig Fischer von Weikersthal and Sebastian Stintzing and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Wolfgang Abenhardt

25 papers receiving 386 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wolfgang Abenhardt Germany	10	230	156	151	118	58	26	396
Levi Pederson United States	10	259 1.1×	88 0.6×	271 1.8×	60 0.5×	46 0.8×	29	422
H. S. Hochster United States	12	430 1.9×	62 0.4×	112 0.7×	130 1.1×	32 0.6×	21	517
Delphine Sénécal France	9	141 0.6×	85 0.5×	115 0.8×	39 0.3×	66 1.1×	20	384
Christopher A. Yasenchak United States	13	270 1.2×	138 0.9×	343 2.3×	77 0.7×	46 0.8×	53	501
Elena Czink Germany	10	180 0.8×	69 0.4×	162 1.1×	79 0.7×	78 1.3×	15	399
Florian Huemer Austria	13	323 1.4×	48 0.3×	79 0.5×	133 1.1×	62 1.1×	46	502
Hua‐Jie Dong China	11	129 0.6×	89 0.6×	129 0.9×	60 0.5×	61 1.1×	21	475
Laurence Hatteville France	8	295 1.3×	46 0.3×	101 0.7×	67 0.6×	41 0.7×	10	384
Yoojoo Lim South Korea	14	201 0.9×	56 0.4×	83 0.5×	117 1.0×	30 0.5×	56	485
Claudia Tellez United States	9	256 1.1×	121 0.8×	82 0.5×	138 1.2×	59 1.0×	13	488

Countries citing papers authored by Wolfgang Abenhardt

Since Specialization

Citations

This map shows the geographic impact of Wolfgang Abenhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Abenhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Abenhardt more than expected).

Fields of papers citing papers by Wolfgang Abenhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang Abenhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Abenhardt. The network helps show where Wolfgang Abenhardt may publish in the future.

Co-authorship network of co-authors of Wolfgang Abenhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Abenhardt. A scholar is included among the top collaborators of Wolfgang Abenhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Abenhardt. Wolfgang Abenhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoechstetter, Manuela A., Wolfgang Knauf, Silvia Dambacher, et al.. (2022). Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany. Clinical Lymphoma Myeloma & Leukemia. 22(8). e777–e787. 1 indexed citations

Knauf, Wolfgang, Wolfgang Abenhardt, Michael Koenigsmann, et al.. (2021). Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms. Hematological Oncology. 39(3). 313–325. 3 indexed citations

Welt, Anja, Marcel Wiesweg, Sarah Theurer, et al.. (2020). Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. Cancer Medicine. 9(13). 4527–4539. 7 indexed citations

Knauf, Wolfgang, et al.. (2020). Rare lymphomas in routine practice—Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms. Hematological Oncology. 38(3). 344–352. 2 indexed citations

Chekerov, Radoslav, Philipp Harter, Stefan Fuxius, et al.. (2017). Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial. PubMed. 4(1). 6–6. 9 indexed citations

Schnell, Oliver, Jun Thorsteinsdottir, Daniel F. Fleischmann, et al.. (2016). Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. Journal of Neuro-Oncology. 130(3). 591–599. 30 indexed citations

Al‐Sawaf, Othman, Kirsten Fischer, Carmen Herling, et al.. (2016). Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. European Journal Of Haematology. 98(3). 254–262. 10 indexed citations

Witzel, Isabell, Volkmar Müller, Wolfgang Abenhardt, et al.. (2014). Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry. BMC Cancer. 14(1). 806–806. 31 indexed citations

Knauf, Wolfgang, et al.. (2014). Routine treatment of patients with chronic lymphocytic leukaemia by office‐based haematologists in Germany—data from the Prospective Tumour Registry Lymphatic Neoplasms. Hematological Oncology. 33(1). 15–22. 15 indexed citations

10.

Knauf, Wolfgang, Wolfgang Abenhardt, Ali Aldaoud, et al.. (2014). Treatment of Non-Transplant Patients with Multiple Myeloma: Routine Treatment by Office-Based Haematologists in Germany - Data from the Prospective Tumour Registry Lymphatic Neoplasms (TLN). Oncology Research and Treatment. 37(11). 635–644. 9 indexed citations

11.

Knauf, Wolfgang, et al.. (2013). Response To 1st-Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry. Blood. 122(21). 4181–4181. 2 indexed citations

12.

Knauf, Wolfgang, et al.. (2012). Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres. Blood. 120(21). 3666–3666. 1 indexed citations

13.

Tesch, Hans, et al.. (2012). Non-Interventional Study Hexafil: G-CSF Use in Accordance to Guidelines?. Blood. 120(21). 2057–2057. 1 indexed citations

14.

Bojko, Peter, et al.. (2012). Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors. Onkologie. 35(1-2). 35–38. 4 indexed citations

15.

Stemmler, Hans‐Joachim, Werner Freier, G. Gitsch, et al.. (2011). Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer. 104(7). 1071–1078. 29 indexed citations

16.

Stintzing, Sebastian, Ludwig Fischer von Weikersthal, Ursula Vehling‐Kaiser, et al.. (2011). Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. British Journal of Cancer. 105(2). 206–211. 22 indexed citations

17.

Stemmler, Hans‐Joachim, Nadia Harbeck, Wolfgang Abenhardt, et al.. (2010). Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer. Oncology. 79(3-4). 197–203. 20 indexed citations

18.

Stemmler, Hans‐Joachim, Nadia Harbeck, Wolfgang Abenhardt, et al.. (2010). Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer. Oncology. 79(3-4). 204–210. 7 indexed citations

19.

Bojko, Peter, Wolfgang Abenhardt, Susanne Schnittger, & Torsten Haferlach. (2009). Mutations in the <i>JAK2</i> and <i>MPL</i> Genes and their Correlation to Clinical Parameters in Patients with Chronic Myeloproliferative Disease. Oncology Research and Treatment. 32(4). 191–195. 3 indexed citations

20.

Schweighofer, Carmen D., Matthias Ritgen, Barbara Eichhorst, et al.. (2008). Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology. 144(1). 95–98. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact